Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals
Abstract
:1. Introduction
2. Material and Methods
2.1. Study Subjects
2.2. Biochemical Measurements
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Suthahar, N.; Meems, L.M.G.; Ho, J.E.; de Boer, R.A. Sex-related differences in contemporary biomarkers for heart failure: A review. Eur. J. Heart Fail. 2020, 22, 775–788. [Google Scholar] [CrossRef] [Green Version]
- Shah, R.V.; Januzzi, J.L., Jr. ST2: A novel remodeling biomarker in acute and chronic heart failure. Curr. Heart Fail. Rep. 2010, 7, 9–14. [Google Scholar] [CrossRef] [PubMed]
- Wu, A.H. Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2. EJIFCC 2012, 23, 98–102. [Google Scholar] [PubMed]
- Mueller, T.; Dieplinger, B. The Presage® ST2 Assay: Analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev. Mol. Diagn. 2013, 13, 13–30. [Google Scholar] [CrossRef]
- Dieplinger, B.; Januzzi, J.L.; Steinmair, M.; Gabriel, C.; Poelz, W.; Haltmayer, M.; Mueller, T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—The Presage™ ST2 assay. Clin. Chim. Acta 2009, 409, 33–40. [Google Scholar] [CrossRef] [PubMed]
- Binas, D.; Daniel, H.; Richter, A.; Ruppert, V.; Schlüter, K.D.; Schieffer, B.; Pankuweit, S. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart 2018, 5, e000750. [Google Scholar] [CrossRef] [PubMed]
- Aimo, A.; Vergaro, G.; Passino, C.; Ripoli, A.; Ky, B.; Miller, W.L.; Bayes-Genis, A.; Anand, I.; Januzzi, J.L.; Emdin, M. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. JACC Heart Fail. 2017, 5, 280–286. [Google Scholar] [CrossRef] [PubMed]
- Aimo, A.; Vergaro, G.; Ripoli, A.; Bayes-Genis, A.; Figal, D.A.P.; de Boer, R.A.; Lassus, J.; Mebazaa, A.; Gayat, E.; Breidthardt, T.; et al. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC Heart Fail. 2017, 5, 287–296. [Google Scholar] [CrossRef]
- Wojciechowska, C.; Romuk, E.; Nowalany-Kozielska, E.; Jacheć, W. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hell. J. Cardiol. 2017, 58, 350–359. [Google Scholar] [CrossRef] [PubMed]
- Laqqan, M.; Schwaighofer, C.; Graeber, S.; Raedle-Hurst, T. Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. PLoS ONE 2018, 13, e0202406. [Google Scholar] [CrossRef] [Green Version]
- Geenen, L.; Baggen, V.J.M.; Bosch, A.E.V.D.; Eindhoven, J.A.; Cuypers, J.A.A.E.; Witsenburg, M.; Boersma, E.; Roos-Hesselink, J.W. Prognostic value of soluble ST2 in adults with congenital heart disease. Heart 2019, 105, 999–1006. [Google Scholar] [CrossRef] [PubMed]
- Lu, J.; Snider, J.V.; Grenache, D.G. Establishment of reference intervals for soluble ST2 from a United States population. Clin. Chim. Acta 2010, 411, 1825–1826. [Google Scholar] [CrossRef] [PubMed]
- Ky, B.; French, B.; McCloskey, K.; Rame, J.E.; McIntosh, E.; Shahi, P.; Dries, D.L.; Tang, W.W.; Wu, A.H.; Fang, J.C.; et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circ. Heart Fail. 2011, 4, 180–187. [Google Scholar] [CrossRef] [Green Version]
- Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 2017, 70, 776–803. [Google Scholar]
- Hauser, J.; Demyanets, S.; Rusai, K.; Goritschan, C.; Weber, M.; Panesar, D.; Rindler, L.; Taylor, A.M.; Marculescu, R.; Burch, M.; et al. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart 2016, 102, 1633–1639. [Google Scholar] [CrossRef]
- You, H.; Jiang, W.; Jiao, M.; Wang, X.; Jia, L.; You, S.; Li, Y.; Wen, H.; Jiang, H.; Yuan, H.; et al. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy. Can. J. Cardiol. 2019, 35, 727–735. [Google Scholar] [CrossRef] [PubMed]
- Caselli, C.; Ragusa, R.; Prontera, C.; Cabiati, M.; Cantinotti, M.; Federico, G.; Del Ry, S.; Trivella, M.G.; Clerico, A. Distribution of circulating cardiac biomarkers in healthy children: From birth through adulthood. Biomarkers Med. 2016, 10, 357–365. [Google Scholar] [CrossRef]
- Meeusen, J.W.; Johnson, J.N.; Gray, A.; Wendt, P.; Jefferies, J.L.; Jaffe, A.S.; Donato, L.J.; Saenger, A.K. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin. Biochem. 2015, 48, 1337–1340. [Google Scholar] [CrossRef] [PubMed]
- Tahmasebi, H.; Higgins, V.; Fung, A.W.S.; Truong, D.; White-Al Habeeb, N.M.A.; Adeli, K. Pediatric Reference Intervals for Biochemical Markers: Gaps and Challenges, Recent National Initiatives and Future Perspectives. EJIFCC 2017, 28, 43–63. [Google Scholar]
- Favresse, J.; Bayart, J.L.; Gruson, D.; Bernardini, S.; Clerico, A.; Perrone, M. The underestimated issue of non-reproducible cardiac troponin I and T results: Case series and systematic review of the literature. Clin Chem Lab Med. 2021, 59, 1201–1211. [Google Scholar] [CrossRef] [PubMed]
- CLSI/IFCC Guideline C28-A3; Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory. CLSI Institute: Wayne, PA, USA, 2008.
- Fernandes, B.A.; Maher, K.O.; Deshpande, S.R. Cardiac biomarkers in pediatric heart disease: A state of art review. World J. Cardiol. 2016, 8, 719–727. [Google Scholar] [CrossRef] [PubMed]
- Lund, L.H.; Rich, M.W.; Hauptman, P.J. Complexities of the Global Heart Failure Epidemic. J. Card. Fail. 2018, 24, 813–814. [Google Scholar] [CrossRef]
- Griffiths, M.; Yang, J.; Simpson, C.E.; Vaidya, D.; Nies, M.; Brandal, S.; Damico, R.; Ivy, D.D.; Austin, E.D.; Pauciulo, M.W.; et al. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest 2021, 160, 297–306. [Google Scholar] [CrossRef] [PubMed]
- From the American Association of Neurological Surgeons (AANS); American Society of Neuroradiology (ASNR); Cardiovascular and Interventional Radiology Society of Europe (CIRSE); Canadian Interventional Radiology Association (CIRA); Congress of Neurological Surgeons (CNS); European Society of Minimally Invasive Neurological Therapy (ESMINT); European Society of Neuroradiology (ESNR); European Stroke Organization (ESO); Society for Cardiovascular Angiography and Interventions (SCAI); Society of Interventional Radiology (SIR); et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int. J. Stroke 2018, 13, 612–632. [Google Scholar]
- Perrone, M.A.; Pomiato, E.; Palmieri, R.; Di Già, G.; Piemonte, F.; Porzio, O.; Gagliardi, M.G. The Effects of Exercise Training on Cardiopulmonary Exercise Testing and Cardiac Biomarkers in Adult Patients with Hypoplastic Left Heart Syndrome and Fontan Circulation. J Cardiovasc Dev Dis. 2022, 9, 171. [Google Scholar] [CrossRef]
- Rowan, C.M.; Pike, F.; Cooke, K.R.; Krance, R.; Carpenter, P.A.; Duncan, C.; Jacobsohn, D.A.; Bollard, C.M.; Cruz, C.R.Y.; Malatpure, A.; et al. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups. Blood 2020, 135, 1428–1437. [Google Scholar] [CrossRef] [PubMed]
- Coglianese, E.E.; Larson, M.; Vasan, R.S.; Ho, J.; Ghorbani, A.; McCabe, E.L.; Cheng, S.; Fradley, M.G.; Kretschman, D.; Gao, W.; et al. Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart Study. Clin. Chem. 2012, 58, 1673–1681. [Google Scholar] [CrossRef]
- Dieplinger, B.; Egger, M.; Poelz, W.; Gabriel, C.; Haltmayer, M.; Mueller, T. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clin. Chem. Lab. Med. 2011, 49, 1515–1518. [Google Scholar] [CrossRef]
n | Median | Mean | SD | 95% CI of the Mean | Reference Interval | 90% CI for Lower Limit of RI | 90% CI for Upper Limit of RI | |
---|---|---|---|---|---|---|---|---|
All donors | 412 | 14.7 | 15.8 | 8.7 | 14.9–16.6 | 2.4–36.4 | 2.4–2.7 | 34.3–40.5 |
All females | 212 | 13.3 | 14.4 | 7.7 | 13.3–15.5 | 2.4–34.3 | 2.4–3.2 | 29.6–37.8 |
All males | 200 | 15.7 | 17.2 | 9.5 | 15.9–18.5 | 2.4–41.6 | 2.4–2.7 | 35.3–45.7 |
Females 0–6 y | 41 | 14.1 | 14.5 | 7.7 | 12.0–16.9 | 3.4–33.6 | 2.4–4.9 | 28.0–39.7 |
Males 0–6 y | 38 | 11.0 | 11.9 | 7.5 | 9.5–14.4 | 1.8–31.7 | 1.0–3.3 | 26.0–38.7 |
Females 7–11 y | 68 | 12.9 | 13.2 | 7.8 | 11.3–15.1 | 2.4–35.6 | 2.4–2.5 | 25.6–37.8 |
Males 7–11 y | 74 | 13.4 | 14.4 | 8.8 | 12.4–16.5 | 1.8–34.2 | 2.4–2.6 | 29.8–38.4 |
Females 12–18 y | 103 | 14.1 | 15.2 | 7.7 | 13.8–16.7 | 3.4–33.8 | 2.6–4.5 | 30.5–37.0 |
Males 12–18 y | 88 | 20.8 | 21.7 | 8.8 | 19.9–23.6 | 6.3–40.6 | 4.6–8.1 | 37.2–44.3 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Perrone, M.A.; Favresse, J.; D’Alessandro, A.; Albanese, F.; De Bruyne, C.; Ceccarelli, S.; Drago, F.; Guccione, P.; Porzio, O.; Leonardi, B. Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals. J. Clin. Med. 2022, 11, 4693. https://doi.org/10.3390/jcm11164693
Perrone MA, Favresse J, D’Alessandro A, Albanese F, De Bruyne C, Ceccarelli S, Drago F, Guccione P, Porzio O, Leonardi B. Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals. Journal of Clinical Medicine. 2022; 11(16):4693. https://doi.org/10.3390/jcm11164693
Chicago/Turabian StylePerrone, Marco Alfonso, Julien Favresse, Annamaria D’Alessandro, Federica Albanese, Coralie De Bruyne, Stefano Ceccarelli, Fabrizio Drago, Paolo Guccione, Ottavia Porzio, and Benedetta Leonardi. 2022. "Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals" Journal of Clinical Medicine 11, no. 16: 4693. https://doi.org/10.3390/jcm11164693
APA StylePerrone, M. A., Favresse, J., D’Alessandro, A., Albanese, F., De Bruyne, C., Ceccarelli, S., Drago, F., Guccione, P., Porzio, O., & Leonardi, B. (2022). Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals. Journal of Clinical Medicine, 11(16), 4693. https://doi.org/10.3390/jcm11164693